273 related articles for article (PubMed ID: 19259097)
41. Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry.
Leinonen MK; Rantanen M; Pitkäniemi J; Malila N
Acta Oncol; 2016 Jun; 55(6):782-6. PubMed ID: 26767306
[TBL] [Abstract][Full Text] [Related]
42. Autoimmune conditions and pancreatic cancer risk in older American adults.
Yuan F; Pfeiffer RM; Julián-Serrano S; Arjani S; Barrett MJ; Koshiol J; Stolzenberg-Solomon RZ
Int J Cancer; 2023 Jan; 152(2):172-182. PubMed ID: 36059225
[TBL] [Abstract][Full Text] [Related]
43. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia.
Landgren O; Engels EA; Pfeiffer RM; Gridley G; Mellemkjaer L; Olsen JH; Kerstann KF; Wheeler W; Hemminki K; Linet MS; Goldin LR
J Natl Cancer Inst; 2006 Sep; 98(18):1321-30. PubMed ID: 16985251
[TBL] [Abstract][Full Text] [Related]
44. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms.
Bennett JM
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):607-609. PubMed ID: 27693133
[TBL] [Abstract][Full Text] [Related]
45. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy.
Rosenthal NS; Farhi DC
Am J Clin Pathol; 1996 Nov; 106(5):676-9. PubMed ID: 8929481
[TBL] [Abstract][Full Text] [Related]
46. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
47. Cytogenetic analysis in myeloid malignancies.
Kueh YK; Tan YO; Suri R; Han P
Ann Acad Med Singap; 1990 Nov; 19(6):802-6. PubMed ID: 2130741
[TBL] [Abstract][Full Text] [Related]
48. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
[TBL] [Abstract][Full Text] [Related]
49. The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.
Fabiani E; Fianchi L; Falconi G; Boncompagni R; Criscuolo M; Guidi F; La Brocca A; Hohaus S; Leone G; Voso MT
Leuk Lymphoma; 2014 Jul; 55(7):1538-43. PubMed ID: 24047476
[TBL] [Abstract][Full Text] [Related]
50. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias.
Freedman MH; Alter BP
Semin Hematol; 2002 Apr; 39(2):128-33. PubMed ID: 11957196
[TBL] [Abstract][Full Text] [Related]
51. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology.
Gowans D; O'Sullivan A; Rollinson S; Roddam P; Groves M; Fegan C; Morgan G; Bowen D
Br J Haematol; 2002 Jun; 117(3):541-5. PubMed ID: 12028020
[TBL] [Abstract][Full Text] [Related]
52. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
53. Autoimmune disease in families with multiple sclerosis: a population-based study.
Ramagopalan SV; Dyment DA; Valdar W; Herrera BM; Criscuoli M; Yee IM; Sadovnick AD; Ebers GC;
Lancet Neurol; 2007 Jul; 6(7):604-10. PubMed ID: 17560172
[TBL] [Abstract][Full Text] [Related]
54. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Phekoo KJ; Richards MA; Møller H; Schey SA;
Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
[TBL] [Abstract][Full Text] [Related]
55. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
Wesner N; Drevon L; Guedon A; Fraison JB; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Eur J Haematol; 2019 Jan; 102(1):63-69. PubMed ID: 30218579
[TBL] [Abstract][Full Text] [Related]
56. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
[TBL] [Abstract][Full Text] [Related]
57. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
58. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Rollison DE; Shain KH; Lee JH; Hampras SS; Fulp W; Fisher K; Al Ali NH; Padron E; Lancet J; Xu Q; Olesnyckyj M; Kenvin L; Knight R; Dalton W; List A; Komrokji RS
Cancer Med; 2016 Jul; 5(7):1694-701. PubMed ID: 27098006
[TBL] [Abstract][Full Text] [Related]
59. [Myelodysplastic syndromes. The epidemiological and etiological aspects].
Aul C; Gattermann N; Germing U; Runde V; Heyll A
Dtsch Med Wochenschr; 1992 Aug; 117(33):1223-31. PubMed ID: 1499520
[TBL] [Abstract][Full Text] [Related]
60. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
